2018
DOI: 10.1186/s12885-018-4764-0
|View full text |Cite
|
Sign up to set email alerts
|

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Abstract: BackgroundTreatment with programmed cell death receptor (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is a promising strategy to lift tumour-induced immune response suppression. However, the current systemic treatment often causes autoimmune side effects. In more than 50% of squamous cell cervical cancer, PD-L1 expression is detected. Moreover, we observed high and interrelated rates of PD-L1 positive macrophages and regulatory T cells in metastatic lymph nodes of cervical cancer patients. As ce… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
21
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 26 publications
(22 citation statements)
references
References 43 publications
1
21
0
Order By: Relevance
“…This analysis compared 11 different ICI-related (grade 1-5 and 3-5) AEs, including a total of 147 studies and 23 761 patients. The interventions were: 46 pembrolizumab articles (n = 6598), 27 nivolumab articles (n = 3576), 13 atezolizumab articles (n = 2787), [76][77][78][79][80][81][82][83][84][85][86][87][88] 12 avelumab articles (n = 3213), [89][90][91][92][93][94][95][96][97][98][99][100][101][102] 10 durvalumab articles (n = 1780), [103][104][105][106][107][108][109][110][111] 22 ipilimumab articles (n = 4067) 5, ; eight tremelimumab articles (n = 1158), [133][134][135][136][137][138][139][140] three JS001 articles (n = 223), [141][142]…”
Section: Basic Characteristics Of the Literaturementioning
confidence: 99%
“…This analysis compared 11 different ICI-related (grade 1-5 and 3-5) AEs, including a total of 147 studies and 23 761 patients. The interventions were: 46 pembrolizumab articles (n = 6598), 27 nivolumab articles (n = 3576), 13 atezolizumab articles (n = 2787), [76][77][78][79][80][81][82][83][84][85][86][87][88] 12 avelumab articles (n = 3213), [89][90][91][92][93][94][95][96][97][98][99][100][101][102] 10 durvalumab articles (n = 1780), [103][104][105][106][107][108][109][110][111] 22 ipilimumab articles (n = 4067) 5, ; eight tremelimumab articles (n = 1158), [133][134][135][136][137][138][139][140] three JS001 articles (n = 223), [141][142]…”
Section: Basic Characteristics Of the Literaturementioning
confidence: 99%
“…Cervical cancer is the fourth leading cause of cancer death in the world and the second most common female malignant tumor, with a mortality rate next only to only that of breast cancer 1 – 3 ; there are ~470,000 new cases of CC each year, and the disease poses a great threat to the life of ~276,000 females 4 . Among these cases, approximately 90% occur in developing countries, and more than 50,000 females succumb to cervical cancer each year in China 5 , 6 . Our current understanding of cervical cancer is that persistent human papillomavirus (HPV) infection contributes to tumor establishment 7 10 .…”
Section: Introductionmentioning
confidence: 99%
“…However, we still need to pave the way to confirm ICB's antitumor activity in CC. [88][89][90][91] Among gynecological malignancies, besides CC, blockading the PD-1/PD-L1 pathway may also be beneficial in ovarian cancer and vulvar cancer. 92,93 Both ovarian cancer and vulvar cancer express high levels of PD-1/PD-L1, and in tumor cells and mouse models, their antitumor immunities were detected via CD8+ T cells and Tregs regulation.…”
Section: Immune Checkpoint Blockadementioning
confidence: 99%